-
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
Friday, January 9, 2026 - 2:52am | 814Read More...Pharmaceuticals giant Merck & Co. Inc. (NYSE:MRK) is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ:RVMD) in a deal potentially valued at between $28 and $32 billion. Shares of Revolution Medicines were up 4.56% on Thursday, before soaring 15.14% overnight...
-
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
Monday, January 29, 2024 - 10:02am | 1335Read More...Markets are primed for a revival in mergers and acquisitions (M&A) in 2024 following the worst performance in almost a decade for deal-making in 2023. Equity and M&A experts believe that, after a year beset by volatile markets and rising interest rates, 2024 offers improving conditions for...
-
EXCLUSIVE: Sanofi In Talks To Buy PTC Therapeutics
Thursday, February 25, 2016 - 2:32pm | 570Read More...Paris-based Sanofi SA (ADR) (NYSE: SNY) has restarted negotiations to acquire New Jersey's PTC Therapeutics, Inc. (NASDAQ: PTCT), a source familiar with the matter told Benzinga on Thursday. Société Générale is said to be working on the deal. Both sides began...
-
Analyst Finds Perrigo 'Still Attractive' As Take Out Target
Wednesday, April 22, 2015 - 11:59am | 248Read More...Despite Perrigo Company plc Ordinary Shares (NYSE: PRGO)'s rejection of a $205 a share offer, the company remains an attractive takeover target, an analyst said Wednesday. "Either now or in the future, we can't rule out broader strategic interest in Perrigo," said J.P. Morgan...
